Search

Your search keyword '"S. Mudaliar"' showing total 41 results

Search Constraints

Start Over You searched for: Author "S. Mudaliar" Remove constraint Author: "S. Mudaliar" Topic hypoglycemic agents Remove constraint Topic: hypoglycemic agents
41 results on '"S. Mudaliar"'

Search Results

1. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.

2. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.

Catalog

Books, media, physical & digital resources

3. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.

4. Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.

5. Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.

6. AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.

7. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.

8. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.

9. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.

10. Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW.

11. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.

12. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.

13. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

14. Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes.

15. Evolution of exenatide as a diabetes therapeutic.

16. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.

17. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes.

18. Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes.

19. Pioglitazone for diabetes prevention in impaired glucose tolerance.

20. Pioglitazone: side effect and safety profile.

21. Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes.

22. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis.

23. Serum glucose control in diabetic patients with cardiovascular disease: should we be less aggressive?

24. Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans.

25. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.

26. Inhaled insulin using AERx insulin Diabetes Management System (AERx iDMS).

27. Diabetes treatments have differential effects on nontraditional cardiovascular risk factors.

28. Effects of the rapid-acting insulin analog glulisine on cultured human skeletal muscle cells: comparisons with insulin and insulin-like growth factor I.

29. Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes.

30. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.

31. Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal.

32. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles.

33. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.

34. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.

35. Insulin therapy in type 2 diabetes.

36. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.

37. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma.

38. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects.

39. Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes

40. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma

41. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects